



ASX & Media Release

Board Changes, Change of Company Secretary and Change of Registered Office and Principal Place of Business Address

Melbourne, Australia; 10 November 2025: Patrys Limited (ASX: PAB, “Patrys” or the “Company”), a therapeutic antibody development company, wishes to advise that Dr James Campbell has tendered his resignation as a Non-Executive Director of the Company, effective as of this day.

Dr Campbell’s tenure with the Company commenced in November 2014, where he was originally a Non-Executive Director from 12 November 2014, then appointed as Managing Director and Chief Executive Officer (CEO) of the Company for the period 13 April 2015 to 30 June 2025. Dr Campbell’s CEO role was made redundant on 1 July 2025. Since 1 July 2025 Dr Campbell has been a Non-Executive Director.

The Board extends its sincere gratitude to James for his valuable contributions and commitment to the Company during his tenure and wish him all the very best for his future endeavours.

The Company is also pleased to announce the appointment of Mr Brian Leedman as a Non-Executive Director, effective 10 November 2025.

Mr Brian Leedman is a seasoned biotechnology executive and company director with more than 20 years of experience in corporate strategy, investor relations, and capital markets within the life sciences sector. He is the founder and former director of ResApp Health Ltd, which was acquired by Pfizer Inc. in 2022, and has held board roles across a range of ASX-listed biotechnology companies, including Neuroscientific Biopharmaceuticals, Neurotech International, Alcidion Corporation, Oncosil and others.

Mr Leedman is currently a Non-Executive Chairman of Blinklab Ltd and has extensive experience guiding emerging biomedical companies from early research through to clinical development and commercialisation. He is well recognised in the Australian biotech community for his leadership in capital raising, corporate governance, and building investor awareness for innovative medical technologies.

Mr Leedman holds a Bachelor of Economics and an MBA from the University of Western Australia. His deep understanding of the biotech industry and proven record of creating shareholder value will provide valuable strategic insight to Patrys as it advances its deoxymab platform through preclinical and clinical development.

Change of Company Secretary

The Company also advises that Mr Johnathon Busing and Mr Kieran Witt have been appointed as Joint Company Secretaries of the Company, with effect from today.



Mr Busing is a Chartered Accountant and the founder of Eleven Corporate, a Perth-based corporate services firm. He has extensive experience in accounting, corporate advisory, governance and ASX compliance, and currently acts as Company Secretary and Chief Financial Officer for a number of ASX-listed companies.

Mr Witt is a Chartered Accountant with extensive experience as a consultant advising ASX listed companies on capital raisings, mergers and acquisitions, statutory accounting requirements and corporate compliance. Currently, he also serves as the Company Secretary for several other ASX-listed companies, where he oversees compliance with corporate governance requirements and regulatory obligations. He is a member of Chartered Accountants Australia and New Zealand and holds a Bachelor of Commerce (Accounting).

Mr Busing and Mr Witt will be the persons responsible for communication with the ASX in relation to Listing Rule matters under Listing Rule 12.6.

As part of this change, Mr Stefan Ross will step down from his role as Company Secretary, effective today. The Board thanks Mr Ross for his contributions to the Company and wishes him well for his future endeavours.

Change of Registered Office and Principal Place of Business Address

Patrys also advises that the registered address and principal place of business for the Company has changed with effect from today to the following:

Office Address: 168 Stirling Highway, Nedlands WA, 6009

Postal Address: PO BOX 369, Nedlands WA, 6909

Telephone: +61 8 6165 8858

-Ends-

This announcement is authorised for release by the Board of Directors of Patrys Limited.

For further information, please contact:

General enquiries

Peter Christie

Non-Executive Chair

P: + 61 3 9670 3273

info@patrys.com

Registered Office Address

168 Stirling Highway

Nedlands WA, 6009



About Patrys Limited

Based in Melbourne, Australia, Patrys (ASX:PAB) is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different indications. More information can be found at www.patrys.com.